Cardiometabolic Disorders News

Supplementation of certain micronutrients benefited cardiometabolic health, but others did not, according to a systematic review and meta-analysis.

Social and economic factors have the greatest impact on COVID-19 outcomes, including an “epidemic” of CV diseases and hospitalizations, and social determinants of health must be addressed to counter disparities, according to a speaker.

Adults with an elevated level of pancreatic fat have higher risk for developing incident diabetes, but weight loss may be able to lower diabetes risk by reducing fat levels and increasing pancreatic volume, according to a presenter.

The benefits of HF medications are additive and incremental and provide similar benefits to patients with ischemic and nonischemic etiologies when initiated simultaneously, according to a speaker.

Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported.

CVD risk increases with the severity of nonalcoholic fatty liver disease, and both CV and liver events are “highly related” to the degree of hepatic fibrosis present, according to a speaker.

Loss of beta cell function serves as the basis for progression from normal glucose tolerance to impaired glucose tolerance, but insulin clearance may not be a major factor in the development of dysglycemia, according to a speaker.

Underlying insulin resistance and hyperinsulinemia work together as “bad actors” to drive atherosclerotic CVD long before a person is diagnosed with type 2 diabetes, and early treatment is needed to slow the process, according to a speaker.

Adults partaking in time-restricted eating have greater decreases in body weight, fat mass, fasting blood glucose and other cardiometabolic markers compared with controls, according to findings from a systematic review and meta-analysis.

Regeneron announced the FDA has accepted for priority review the supplemental biologics license application for evinacumab-dgnb as adjunctive treatment for homozygous familial hypercholesterolemia in children aged 5 to 11 years.